Background Mild cognitive impairment (MCI) may represent a preclinical stage of
Alzheimer's disease. Early treatment of MCI may delay the development of dementia …

Objectives Mild cognitive impairment (MCI) is etiologically heterogeneous, and a substantial
proportion of MCI subjects will develop different dementia disorders. One subtype of this …

Mild cognitive impairment (MCI), poorly defined for many years, has recently been described
as a transition state from healthy cognitive ageing into dementia. This intrinsic heterogeneity …

Mild cognitive impairment (MCI) refers to memory deficits in excess of normal aging, but not
sufficient for the diagnosis of Alzheimer's disease (AD). In general, patients with MCI are not …

Introduction Several studies have tested the N‐methyl‐D‐aspartate–receptor antagonist
memantine as an add‐on to pre‐existing treatment with acetylcholinesterase inhibitors. The …

OBJECTIVE: To present a general overview of the etiology, definition, and prevalence of
mild cognitive impairment (MCI), as well as outline possible treatment strategies. DATA …

The concept of mild cognitive impairment (MCI) identifies persons who are neither
cognitively normal nor demented. There is increasing evidence that MCI defines a group of …

Mild cognitive impairment (MCI) is an operational definition for a cognitive decline in
individuals with a greater risk of developing dementia. The amnestic subtype of MCI is of …

Background For patients with moderate to severe Alzheimer's disease (AD), treatment
guidelines recommend adding memantine when symptoms of the disease are not well …

Background: Acetylcholinesterase inhibitor (AChEI) and Memantine are recognized drug
treatments with limited clinical efficacy. Combination therapy for patients with Alzheimer's …